Aktienanalyse zu Incyte Corp (INCY)INCYIncyte Corp

Incyte Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics. It operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise consists of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. It also includes VGA039, a novel monoclonal antibody in Phase III development for von Willebrand disease (VWD). It manages business activities through the development and commercialization of oncology and dermatology products. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Incyte Corp is currently priced at $113.07, which is below the average analyst price target of $126.75 (from $99 to $157). The company's forward P/E ratio is 14.71, indicating reasonable valuation compared to growth prospects. However, the RSI is at 45.46, suggesting the stock is neither overbought nor oversold, and the recent 20-day change of -9.77% indicates a downward trend. Given these mixed signals, it may be prudent to hold rather than buy at this moment.

21 analysts cover INCY: 17 rate it Buy, 4 Hold and 0 Sell. The average price target is 100.31.